DrugPatentWatch Database Preview
Patent: 10,106,621
Summary for Patent: 10,106,621
| Title: | Immunotherapeutic molecules and uses |
| Abstract: | The invention provides molecule comprising: (i) a targeting moiety capable of directly or indirectly targeting to unwanted cells, and (ii) a further moiety that has a masked immune cell binding region so as to prevent binding of the further moiety to an immune cell, wherein the masked immune cell binding region is capable of being selectively unmasked when the molecule is in the vicinity of the unwanted cells so as to allow binding of the further moiety to an immune cell. |
| Inventor(s): | Cobbold; Mark (Winchester, MA), Millar; David (Winchester, MA) |
| Assignee: | The University of Birmingham (Birmingham, GB) |
| Application Number: | 15/708,419 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,106,621
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | ⤷ Free Forever Trial | The University of Birmingham (Birmingham, GB) | 2032-02-28 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | ⤷ Free Forever Trial | The University of Birmingham (Birmingham, GB) | 2032-02-28 | RX | Orphan | search |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | ⤷ Free Forever Trial | The University of Birmingham (Birmingham, GB) | 2032-02-28 | RX | Orphan | search |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 002 | 1997-11-26 | ⤷ Free Forever Trial | The University of Birmingham (Birmingham, GB) | 2032-02-28 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | ⤷ Free Forever Trial | The University of Birmingham (Birmingham, GB) | 2032-02-28 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 10,106,621
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2013128194 | ⤷ Free Forever Trial |
| United States of America | 2015183875 | ⤷ Free Forever Trial |
| United States of America | 2016039942 | ⤷ Free Forever Trial |
| United States of America | 2018105599 | ⤷ Free Forever Trial |
| United States of America | 9650445 | ⤷ Free Forever Trial |
| United States of America | 9822180 | ⤷ Free Forever Trial |
| >Country | >Patent Number | >Estimated Expiration |
